• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过测量原发性进行性失语症患者与健康相关的生活质量来评估疾病影响。

Assessment of disease impact through health-related quality of life measurement in primary progressive aphasia.

作者信息

Hopkins Thomas, Kwon Eunbi, Lapins Allison, Gill Nathan, Roberts Angela, Rogalski Emily

机构信息

Department of Neurology Biologic Sciences Division, Healthy Aging and Alzheimer's Research Care Center University of Chicago Chicago Illinois USA.

Mesulam Center for Cognitive Neurology and Alzheimer's Disease Northwestern University Feinberg School of Medicine Chicago Illinois USA.

出版信息

Alzheimers Dement (N Y). 2024 Nov 26;10(4):e12499. doi: 10.1002/trc2.12499. eCollection 2024 Oct-Dec.

DOI:10.1002/trc2.12499
PMID:39748847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11694525/
Abstract

INTRODUCTION

Measurements of health-related quality of life (HRQoL) are important for capturing disease impact beyond physical health and relative to other diseases but have rarely been assessed in primary progressive aphasia (PPA).

METHODS

HRQoL was characterized overall, by sex and subtype in PPA ( = 118) using the Health Utilities Index-2/3 (HUI2/3). Multiple linear regression assessed associations between HRQoL and language severity.

RESULTS

Multi-attribute HUI2/3 summary scores indicated moderate to severe impairment. Scores did not differ by sex and were more severe for semantic than non-semantic PPA. Language severity scores showed significant associations with HUI multi-attribute scores and select single-attribute measures (hearing, sensation, cognition, and speech) with less language impairment associated with better functional capacity related to HRQoL.

DISCUSSION

This study identified poor HRQoL in a relatively large PPA cohort. HRQoL measures aid in determining patient perspective, policy decision making, and resource allocation. Results may be used to advocate for PPA support.

HIGHLIGHTS

Primary progressive aphasia (PPA) negatively impacts health-related quality of life.Health utilities index scores are associated with Western Aphasia Battery performance in PPA.Severity of language impairment in PPA is associated with poorer quality of life.

摘要

引言

健康相关生活质量(HRQoL)的测量对于了解疾病对身体健康之外的影响以及与其他疾病相比的影响非常重要,但在原发性进行性失语症(PPA)中很少进行评估。

方法

使用健康效用指数-2/3(HUI2/3)对118例PPA患者的总体、按性别和亚型的HRQoL进行了特征描述。多元线性回归评估了HRQoL与语言严重程度之间的关联。

结果

多属性HUI2/3汇总评分表明存在中度至重度损害。评分在性别上没有差异,语义性PPA比非语义性PPA更严重。语言严重程度评分与HUI多属性评分以及选定的单属性测量(听力、感觉、认知和言语)显示出显著关联,语言损害越少,与HRQoL相关的功能能力越好。

讨论

本研究在一个相对较大的PPA队列中发现HRQoL较差。HRQoL测量有助于确定患者的观点、政策决策和资源分配。结果可用于倡导对PPA的支持。

要点

原发性进行性失语症(PPA)对健康相关生活质量有负面影响。健康效用指数评分与PPA中的西方失语症成套测验表现相关。PPA中语言损害的严重程度与较差的生活质量相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9944/11694525/8d8675c9b215/TRC2-10-e12499-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9944/11694525/de372a7f18c9/TRC2-10-e12499-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9944/11694525/bdd2d24b808a/TRC2-10-e12499-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9944/11694525/8d8675c9b215/TRC2-10-e12499-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9944/11694525/de372a7f18c9/TRC2-10-e12499-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9944/11694525/bdd2d24b808a/TRC2-10-e12499-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9944/11694525/8d8675c9b215/TRC2-10-e12499-g001.jpg

相似文献

1
Assessment of disease impact through health-related quality of life measurement in primary progressive aphasia.通过测量原发性进行性失语症患者与健康相关的生活质量来评估疾病影响。
Alzheimers Dement (N Y). 2024 Nov 26;10(4):e12499. doi: 10.1002/trc2.12499. eCollection 2024 Oct-Dec.
2
Non-pharmacological interventions for improving language and communication in people with primary progressive aphasia.原发性进行性失语症患者语言和交流能力的非药物干预措施。
Cochrane Database Syst Rev. 2024 May 29;5(5):CD015067. doi: 10.1002/14651858.CD015067.pub2.
3
Positive effects of speech and language therapy group interventions in primary progressive aphasia: A systematic review.言语语言治疗小组干预对原发性进行性失语症的积极影响:系统评价。
Int J Lang Commun Disord. 2024 Sep-Oct;59(5):1832-1849. doi: 10.1111/1460-6984.13031. Epub 2024 Apr 11.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Association of Regional Cortical Network Atrophy With Progression to Dementia in Patients With Primary Progressive Aphasia.区域皮质网络萎缩与原发性进行性失语症患者向痴呆进展的关联。
Neurology. 2023 Jan 17;100(3):e286-e296. doi: 10.1212/WNL.0000000000201403. Epub 2022 Oct 3.
6
Exercise interventions on health-related quality of life for people with cancer during active treatment.积极治疗期间针对癌症患者健康相关生活质量的运动干预措施。
Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD008465. doi: 10.1002/14651858.CD008465.pub2.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
8
Calcium channel blockers for primary and secondary Raynaud's phenomenon.用于原发性和继发性雷诺现象的钙通道阻滞剂。
Cochrane Database Syst Rev. 2017 Dec 13;12(12):CD000467. doi: 10.1002/14651858.CD000467.pub2.
9
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
10
Efficacy of Communication Bridge-2 for primary progressive aphasia: A randomized controlled trial of communication intervention.沟通桥梁 - 2对原发性进行性失语症的疗效:一项沟通干预的随机对照试验
Alzheimers Dement. 2025 Mar;21(3):e70088. doi: 10.1002/alz.70088.

本文引用的文献

1
Behavioral Treatment for Speech and Language in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech: A Systematic Review.原发性进行性失语症和原发性进行性运动性构音障碍的言语和语言行为治疗:系统评价。
Neuropsychol Rev. 2024 Sep;34(3):882-923. doi: 10.1007/s11065-023-09607-1. Epub 2023 Oct 4.
2
Symptom-led staging for semantic and non-fluent/agrammatic variants of primary progressive aphasia.以症状为导向的原发性进行性失语症的语义和非流畅/语法障碍亚型分期。
Alzheimers Dement. 2024 Jan;20(1):195-210. doi: 10.1002/alz.13415. Epub 2023 Aug 7.
3
Quality of Life Ratings and Proxy Bias in Primary Progressive Aphasia: Two Sides to the Story?
原发性进行性失语症中的生活质量评分和代理偏见:故事的两面?
Am J Alzheimers Dis Other Demen. 2023 Jan-Dec;38:15333175231177668. doi: 10.1177/15333175231177668.
4
Socioeconomic Status and Quality of Life: An Assessment of the Mediating Effect of Social Capital.社会经济地位与生活质量:社会资本中介效应评估
Healthcare (Basel). 2023 Mar 3;11(5):749. doi: 10.3390/healthcare11050749.
5
Communication Bridge™-2 (CB2): an NIH Stage 2 randomized control trial of a speech-language intervention for communication impairments in individuals with mild to moderate primary progressive aphasia.沟通桥梁™-2 (CB2):美国国立卫生研究院 2 期随机对照试验,针对轻度至中度原发性进行性失语症患者的言语语言干预以改善沟通障碍。
Trials. 2022 Jun 13;23(1):487. doi: 10.1186/s13063-022-06162-7.
6
The Reliability of Telepractice Administration of the Western Aphasia Battery-Revised in Persons With Primary Progressive Aphasia.原发性进行性失语患者中使用远程实践方式管理西方失语症成套测验-修订版的信度。
Am J Speech Lang Pathol. 2022 Mar 10;31(2):881-895. doi: 10.1044/2021_AJSLP-21-00150. Epub 2022 Feb 17.
7
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.用于早期阿尔茨海默病患者的阿杜卡奴单抗的成本效益和基于价值的定价。
Neurology. 2022 Mar 1;98(9):e968-e977. doi: 10.1212/WNL.0000000000013314. Epub 2022 Jan 12.
8
Health-Related Quality of Life Measurement in Public Health.公共卫生领域中与健康相关的生活质量测量
Annu Rev Public Health. 2022 Apr 5;43:355-373. doi: 10.1146/annurev-publhealth-052120-012811. Epub 2021 Dec 9.
9
The effectiveness and value of aducanumab for Alzheimer's disease.阿杜卡奴单抗治疗阿尔茨海默病的疗效和价值。
J Manag Care Spec Pharm. 2021 Nov;27(11):1613-1617. doi: 10.18553/jmcp.2021.27.11.1613.
10
Measuring health-related quality of life in patients with rare disease.测量罕见病患者与健康相关的生活质量。
J Patient Rep Outcomes. 2021 Jul 20;5(1):61. doi: 10.1186/s41687-021-00336-8.